Radiopharmaceutical developer Molecular Insight Pharmaceuticals has signed an agreement with the Centre for Probe Development and Commercialization in Canada to manufacture a new radiopharmaceutical designed to deliver therapeutic doses of radiation directly to metastatic prostate cancer.
The radiopharmaceutical, iodine-131 (I-131) MIP-1466, would be the first small-molecule-based radiopharmaceutical to specifically target prostate-specific membrane antigen (PSMA), a type of protein expressed in high levels on prostate tumors.
It is scheduled to begin clinical trials early next year.
